AKVA group ASA: Update on intragroup merger with AKVA group Software AS and Polarcirkel AS
Klepp, 7 November 2024: Reference is made to the stock exchange announcement by AKVA group ASA (AKVA) on 26 September 2024 regarding the entering into of merger plans for the…
Form 8.5 (EPT/RI) – Brown (N) Group Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY…
Duos Edge AI Acquires Additional Edge Data Centers
JACKSONVILLE, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), through its operating subsidiary Duos Edge AI, Inc. (“Duos Edge AI”), a…
Victory Bancorp, Inc. Declares Quarterly Dividend
LIMERICK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Victory Bancorp, Inc. (OTCQX:VTYB), today announced that its Board of Directors has declared a quarterly cash dividend of $0.0650 per outstanding share…
CSW Industrials Deploys $40 Million of Acquisition Capital in Profitable Plumbing End Market
Investment Highlights Capital investment of $40 million for acquisition of PF Waterworks, LP, which offers innovative, eco-friendly drain management solutionsValuation represents approximately 9.5x PF Waterworks’ trailing twelve-months’ EBITDAExpected to be…
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate of 55%…
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with…
Aptean Expands Warehouse Management Capabilities Through Acquisition of Indigo Software
ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Today, Aptean, a global provider of mission-critical enterprise software solutions, announced the acquisition of Indigo Software Limited (“Indigo Software”), a provider of…
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well tolerated, with no reports of…
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion…